| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
53,787 |
47,640 |
$7.77M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
59,845 |
54,244 |
$6.24M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
104,844 |
91,786 |
$3.24M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
45,334 |
41,489 |
$3.07M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
19,212 |
15,650 |
$1.82M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
29,538 |
24,275 |
$1.08M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
21,033 |
19,433 |
$1.05M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
30,895 |
26,954 |
$893K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
18,072 |
14,237 |
$854K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
19,274 |
18,126 |
$754K |
| 71045 |
Radiologic examination, chest; single view |
26,625 |
23,540 |
$568K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
26,021 |
9,078 |
$548K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
88,087 |
76,485 |
$458K |
| 80053 |
Comprehensive metabolic panel |
64,208 |
56,027 |
$448K |
| 70450 |
Computed tomography, head or brain; without contrast material |
4,187 |
3,666 |
$442K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
2,426 |
1,674 |
$416K |
| 20610 |
|
3,488 |
2,985 |
$392K |
| 62323 |
|
1,262 |
1,078 |
$349K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
14,352 |
3,434 |
$335K |
| 87632 |
|
2,198 |
1,976 |
$308K |
| 64493 |
|
567 |
386 |
$303K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,359 |
5,693 |
$281K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,099 |
3,653 |
$270K |
| 31237 |
|
1,123 |
658 |
$253K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,264 |
4,844 |
$251K |
| 36415 |
Collection of venous blood by venipuncture |
111,398 |
92,599 |
$237K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
734 |
661 |
$212K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
8,945 |
6,685 |
$200K |
| 42830 |
|
356 |
320 |
$193K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,057 |
2,622 |
$179K |
| 81025 |
|
25,745 |
22,975 |
$148K |
| 87631 |
|
1,048 |
1,013 |
$140K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
376 |
324 |
$137K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,229 |
3,637 |
$126K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,452 |
833 |
$113K |
| 84484 |
|
15,807 |
12,883 |
$113K |
| G0378 |
Hospital observation service, per hour |
922 |
468 |
$110K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
658 |
593 |
$104K |
| 81001 |
|
47,406 |
41,501 |
$103K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,038 |
1,488 |
$101K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
376 |
339 |
$99K |
| 73560 |
|
2,582 |
1,584 |
$87K |
| 73610 |
|
2,011 |
1,722 |
$81K |
| 73630 |
|
1,577 |
1,269 |
$76K |
| 95886 |
|
336 |
294 |
$76K |
| 64494 |
|
880 |
349 |
$70K |
| 20611 |
|
268 |
233 |
$68K |
| 20550 |
|
641 |
399 |
$64K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
11,082 |
9,651 |
$63K |
| 27096 |
|
92 |
66 |
$63K |
| 72100 |
|
1,226 |
1,027 |
$62K |
| 71046 |
Radiologic examination, chest; 2 views |
2,369 |
2,199 |
$62K |
| 64635 |
|
83 |
68 |
$59K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,977 |
1,699 |
$55K |
| 83880 |
|
2,760 |
2,433 |
$55K |
| 80061 |
Lipid panel |
4,937 |
4,588 |
$54K |
| 83690 |
|
9,926 |
8,933 |
$49K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,304 |
1,244 |
$49K |
| 83735 |
|
12,147 |
10,545 |
$49K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,636 |
2,252 |
$49K |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
693 |
616 |
$48K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,322 |
3,091 |
$48K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
190 |
178 |
$48K |
| 20526 |
|
283 |
238 |
$44K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
318 |
284 |
$44K |
| 31231 |
|
119 |
103 |
$43K |
| 62321 |
|
157 |
137 |
$42K |
| 73030 |
|
1,004 |
739 |
$37K |
| 82553 |
|
7,225 |
5,765 |
$37K |
| 75574 |
|
238 |
197 |
$37K |
| 82550 |
|
9,361 |
7,787 |
$36K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
1,388 |
788 |
$33K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
4,320 |
4,039 |
$32K |
| 73130 |
|
722 |
539 |
$31K |
| C1769 |
Guide wire |
127 |
109 |
$31K |
| J0185 |
Injection, aprepitant, 1 mg |
105 |
62 |
$30K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,000 |
940 |
$30K |
| 69210 |
|
866 |
783 |
$29K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,045 |
912 |
$29K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
357 |
322 |
$29K |
| 64721 |
|
167 |
120 |
$29K |
| 94060 |
|
520 |
467 |
$29K |
| 83970 |
|
1,700 |
1,405 |
$29K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
6,400 |
5,215 |
$28K |
| 73564 |
|
544 |
392 |
$28K |
| 72040 |
|
621 |
537 |
$27K |
| 31575 |
|
106 |
76 |
$26K |
| 97161 |
|
461 |
422 |
$25K |
| 84439 |
|
2,832 |
2,628 |
$23K |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
93 |
74 |
$22K |
| 80076 |
|
3,956 |
3,567 |
$22K |
| 87088 |
|
3,346 |
3,042 |
$21K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
885 |
790 |
$20K |
| 83605 |
|
2,858 |
2,400 |
$19K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
12,237 |
10,138 |
$19K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,384 |
1,272 |
$19K |
| 64636 |
|
139 |
67 |
$19K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,490 |
683 |
$19K |
| 76830 |
Ultrasound, transvaginal |
205 |
191 |
$18K |
| 94729 |
|
555 |
502 |
$18K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
489 |
93 |
$17K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
127 |
111 |
$16K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,574 |
3,988 |
$15K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
81 |
50 |
$14K |
| 36591 |
|
295 |
161 |
$12K |
| 82565 |
|
3,134 |
2,886 |
$12K |
| 94726 |
|
168 |
161 |
$12K |
| 92567 |
|
1,103 |
1,035 |
$11K |
| 85730 |
|
3,447 |
3,005 |
$11K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
141 |
136 |
$11K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
43 |
40 |
$11K |
| 92587 |
|
299 |
293 |
$11K |
| 71250 |
|
148 |
135 |
$11K |
| 85610 |
|
3,963 |
3,436 |
$10K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
71 |
24 |
$9K |
| 93017 |
|
85 |
81 |
$9K |
| 73502 |
|
170 |
155 |
$8K |
| 81003 |
|
5,287 |
4,582 |
$8K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
267 |
246 |
$8K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
265 |
245 |
$8K |
| 84100 |
|
3,256 |
2,837 |
$8K |
| 95909 |
|
51 |
47 |
$8K |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
765 |
580 |
$8K |
| 80305 |
|
631 |
563 |
$7K |
| 76801 |
|
106 |
96 |
$7K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
180 |
171 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
255 |
228 |
$7K |
| 84460 |
|
1,310 |
1,226 |
$7K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
77 |
38 |
$6K |
| 84450 |
|
1,298 |
1,210 |
$6K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
481 |
372 |
$6K |
| 82077 |
|
692 |
605 |
$6K |
| 80050 |
General health panel |
145 |
136 |
$6K |
| J3490 |
Unclassified drugs |
2,665 |
2,034 |
$6K |
| 82570 |
|
2,277 |
1,935 |
$6K |
| 95806 |
|
79 |
72 |
$5K |
| 86140 |
|
1,599 |
1,421 |
$5K |
| 82728 |
|
463 |
420 |
$5K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
206 |
107 |
$5K |
| 82947 |
|
1,347 |
1,259 |
$5K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
5,227 |
3,898 |
$5K |
| 84466 |
|
580 |
514 |
$5K |
| 84550 |
|
2,221 |
1,896 |
$5K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
69 |
52 |
$5K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
1,266 |
433 |
$4K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
13 |
13 |
$4K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
2,772 |
2,301 |
$4K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
16 |
13 |
$4K |
| 84156 |
|
2,170 |
1,836 |
$4K |
| 72141 |
|
12 |
12 |
$4K |
| 82962 |
|
3,928 |
2,836 |
$4K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
234 |
142 |
$4K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
34,192 |
24,724 |
$4K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
81 |
71 |
$4K |
| 73620 |
|
88 |
79 |
$4K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
69 |
59 |
$3K |
| 73600 |
|
86 |
80 |
$3K |
| 95911 |
|
14 |
13 |
$3K |
| 87641 |
|
114 |
104 |
$3K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
17 |
14 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
136 |
124 |
$3K |
| 84520 |
|
762 |
725 |
$3K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
180 |
171 |
$3K |
| 94618 |
|
124 |
114 |
$3K |
| 85027 |
|
694 |
625 |
$3K |
| 83540 |
|
670 |
562 |
$3K |
| 74170 |
|
12 |
12 |
$3K |
| 96417 |
|
21 |
13 |
$2K |
| 86160 |
|
374 |
164 |
$2K |
| 93296 |
|
390 |
328 |
$2K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,853 |
2,457 |
$2K |
| 20605 |
|
13 |
12 |
$2K |
| 85055 |
|
101 |
63 |
$2K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
57 |
52 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
14 |
14 |
$2K |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
119 |
109 |
$2K |
| 86038 |
|
185 |
143 |
$2K |
| 90686 |
|
357 |
320 |
$2K |
| 73110 |
|
58 |
41 |
$2K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
194 |
164 |
$2K |
| 70360 |
|
63 |
60 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,935 |
1,603 |
$2K |
| 92557 |
|
27 |
24 |
$2K |
| 84703 |
|
284 |
252 |
$2K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
2,129 |
1,698 |
$2K |
| 96376 |
|
29 |
14 |
$1K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
1,097 |
539 |
$1K |
| 86200 |
|
128 |
115 |
$1K |
| 64495 |
|
23 |
17 |
$1K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
32 |
26 |
$1K |
| 86255 |
|
127 |
113 |
$1K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
375 |
335 |
$1K |
| 31000 |
|
77 |
61 |
$1K |
| 90677 |
|
18 |
13 |
$1K |
| J1644 |
Injection, heparin sodium, per 1000 units |
81 |
40 |
$1K |
| 84145 |
|
73 |
68 |
$1K |
| J7510 |
Prednisolone oral, per 5 mg |
679 |
643 |
$1K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
55 |
12 |
$996.74 |
| 80320 |
|
84 |
76 |
$941.54 |
| 99215 |
Prolong outpt/office vis |
14 |
14 |
$745.99 |
| 85379 |
|
98 |
90 |
$709.22 |
| J2704 |
Injection, propofol, 10 mg |
6,982 |
4,577 |
$656.62 |
| 87040 |
|
124 |
67 |
$626.55 |
| 86430 |
|
121 |
108 |
$583.04 |
| 86803 |
|
47 |
44 |
$577.47 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
261 |
191 |
$573.52 |
| 82150 |
|
123 |
117 |
$557.56 |
| 85652 |
|
268 |
229 |
$540.35 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
111 |
103 |
$512.25 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
259 |
234 |
$470.64 |
| 86235 |
|
33 |
16 |
$429.57 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
68 |
61 |
$415.19 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
269 |
153 |
$396.71 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
14 |
12 |
$394.67 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
205 |
180 |
$386.81 |
| 87186 |
|
70 |
56 |
$371.42 |
| 82043 |
|
80 |
77 |
$315.96 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
155 |
102 |
$307.30 |
| 84481 |
|
29 |
26 |
$279.34 |
| 99407 |
|
364 |
291 |
$261.19 |
| 59430 |
|
12 |
12 |
$209.02 |
| 90688 |
|
148 |
133 |
$207.80 |
| 87420 |
|
15 |
14 |
$204.06 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
177 |
170 |
$202.42 |
| 87077 |
|
28 |
24 |
$199.53 |
| 84702 |
|
24 |
13 |
$196.25 |
| 90656 |
|
37 |
32 |
$181.64 |
| 83615 |
|
34 |
27 |
$134.03 |
| 93298 |
|
12 |
12 |
$128.76 |
| 87210 |
|
26 |
12 |
$110.88 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
461 |
200 |
$87.50 |
| 84134 |
|
13 |
13 |
$82.84 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
12 |
12 |
$76.60 |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
97 |
88 |
$74.88 |
| 85046 |
|
13 |
13 |
$73.07 |
| 86850 |
|
14 |
12 |
$68.44 |
| 82951 |
|
14 |
13 |
$65.65 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
31 |
27 |
$58.86 |
| 85045 |
|
12 |
12 |
$53.64 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
13 |
13 |
$50.72 |
| J1630 |
Injection, haloperidol, up to 5 mg |
16 |
14 |
$46.99 |
| 86901 |
|
14 |
12 |
$30.38 |
| 86900 |
|
14 |
12 |
$30.38 |
| 99406 |
|
42 |
38 |
$27.88 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
17 |
17 |
$22.33 |
| J2060 |
Injection, lorazepam, 2 mg |
14 |
13 |
$20.67 |
| 82952 |
|
14 |
13 |
$20.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
14 |
14 |
$9.55 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
11,793 |
10,990 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
815 |
404 |
$0.00 |
| A9270 |
Non-covered item or service |
535 |
428 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
111 |
104 |
$0.00 |
| 74420 |
|
19 |
12 |
$0.00 |
| 88304 |
|
241 |
172 |
$0.00 |
| 00000 |
|
326 |
270 |
$0.00 |
| 51798 |
|
37 |
35 |
$0.00 |
| Q4186 |
Epifix, per square centimeter (add-on, list separately in addition to primary procedure) |
16 |
13 |
$0.00 |
| 88312 |
|
338 |
200 |
$0.00 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
82 |
50 |
$0.00 |
| 02414 |
|
33 |
32 |
$0.00 |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
20 |
13 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
13 |
12 |
$0.00 |